Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
Rift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | Inglés |
| Published: |
Elsevier
2020
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10568/109976 |
| _version_ | 1855530806555967488 |
|---|---|
| author | Wright, D. Allen, E.R. Clark, M.H.A. Gitonga, J.N. Karanja, H.K. Hulswit, R.J.G. Taylor, I. Biswas, S. Marshall, J. Mwololo, D. Muriuki, J. Bett, Bernard K. Bowden, T.A. Warimwe, G.M. |
| author_browse | Allen, E.R. Bett, Bernard K. Biswas, S. Bowden, T.A. Clark, M.H.A. Gitonga, J.N. Hulswit, R.J.G. Karanja, H.K. Marshall, J. Muriuki, J. Mwololo, D. Taylor, I. Warimwe, G.M. Wright, D. |
| author_facet | Wright, D. Allen, E.R. Clark, M.H.A. Gitonga, J.N. Karanja, H.K. Hulswit, R.J.G. Taylor, I. Biswas, S. Marshall, J. Mwololo, D. Muriuki, J. Bett, Bernard K. Bowden, T.A. Warimwe, G.M. |
| author_sort | Wright, D. |
| collection | Repository of Agricultural Research Outputs (CGSpace) |
| description | Rift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target the viral envelope glycoproteins. However, naturally acquired immunity to RVF in humans is poorly described. Here, we characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated with nAb titers. These data are consistent with the greater level of immune accessibility of Gn on the viral envelope surface and confirm the importance of Gn as an integral component for RVF vaccine development. |
| format | Journal Article |
| id | CGSpace109976 |
| institution | CGIAR Consortium |
| language | Inglés |
| publishDate | 2020 |
| publishDateRange | 2020 |
| publishDateSort | 2020 |
| publisher | Elsevier |
| publisherStr | Elsevier |
| record_format | dspace |
| spelling | CGSpace1099762025-01-28T07:08:05Z Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein Wright, D. Allen, E.R. Clark, M.H.A. Gitonga, J.N. Karanja, H.K. Hulswit, R.J.G. Taylor, I. Biswas, S. Marshall, J. Mwololo, D. Muriuki, J. Bett, Bernard K. Bowden, T.A. Warimwe, G.M. immunology virology rift valley fever virus Rift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target the viral envelope glycoproteins. However, naturally acquired immunity to RVF in humans is poorly described. Here, we characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated with nAb titers. These data are consistent with the greater level of immune accessibility of Gn on the viral envelope surface and confirm the importance of Gn as an integral component for RVF vaccine development. 2020-11 2020-10-26T13:06:12Z 2020-10-26T13:06:12Z Journal Article https://hdl.handle.net/10568/109976 en Open Access Elsevier Wright, D., Allen, E.R., Clark, M.H.A., Gitonga, J.N., Karanja, H.K., Hulswit, R.J.G., Taylor, I., Biswas, S., Marshall, J., Mwololo, D., Muriuki, J., Bett, B., Bowden, T.A. and Warimwe, G.M. 2020. Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein. iScience 23(11): 101669. |
| spellingShingle | immunology virology rift valley fever virus Wright, D. Allen, E.R. Clark, M.H.A. Gitonga, J.N. Karanja, H.K. Hulswit, R.J.G. Taylor, I. Biswas, S. Marshall, J. Mwololo, D. Muriuki, J. Bett, Bernard K. Bowden, T.A. Warimwe, G.M. Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title | Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title_full | Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title_fullStr | Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title_full_unstemmed | Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title_short | Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein |
| title_sort | naturally acquired rift valley fever virus neutralizing antibodies predominantly target the gn glycoprotein |
| topic | immunology virology rift valley fever virus |
| url | https://hdl.handle.net/10568/109976 |
| work_keys_str_mv | AT wrightd naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT allener naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT clarkmha naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT gitongajn naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT karanjahk naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT hulswitrjg naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT taylori naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT biswass naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT marshallj naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT mwololod naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT muriukij naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT bettbernardk naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT bowdenta naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein AT warimwegm naturallyacquiredriftvalleyfevervirusneutralizingantibodiespredominantlytargetthegnglycoprotein |